Agonist peptide dimers

Patent 5767078 Issued on June 16, 1998. Estimated Expiration Date:

June 16, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Inventors

Application

No. 484135 filed on 06/07/1995

US Classes:

514/12, 25 or more peptide repeating units in known peptide chain structure514/13, 16 to 24 peptide repeating units in known peptide chain514/14, 12 to 15 peptide repeating units in known peptide chain514/15, 9 to 11 peptide repeating units in known peptide chain530/300, PEPTIDES OF 3 TO 100 AMINO ACID RESIDUES530/324, 25 or more amino acid residues in defined sequence530/326, 15 to 23 amino acid residues in defined sequence530/345Chemical aftertreatment, e.g., acylation, methylation, etc.

Examiners

Primary: Tsang, Cecilia J.
Assistant: Harle, Jennifer

Attorney, Agent or Firm

Wallen, III; John W.

Foreign Patent References

WO 90/08822 WO. 08/13/1990

International Classes

A61K 038/00
C07K 002/00
C07K 005/00
C07K 007/00

Abstract

The present invention is directed to the dimerization of agonists and antagonists of cell surface receptors and particularly to peptide dimers which behave as cell surface receptor agonists in their dimeric form. Such receptors belong to the dimerization-mediated activation class often observed among receptors for growth and differentiation factors. The agonists of this class of receptors is understood to effect dimerization of the receptor and thus signal initiation. The present invention exemplifies dimers of erythropoietin (EPO) agonists and antagonists comprising a core amino acid sequence of X3 X4 X5 GPX6 TWX7 X8 (SEQ ID NO: 1) wherein each amino acid is indicated by standard one letter abbreviation; X3 can be C, A, ଱-amino-γ-bromobutyric acid or Hoc; X4 can be R, H, L or W; X5 can be M, F, or I; X6 is independently selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids; X7 can be D, E, I, L or V; and X8 can be C, A, ଱-amino-γ-bromobutyric acid or Hoc, provided that either X3 or X8 is C or Hoc.

Other References

Vedovato et al. (1984) Acta. Haematol. 71:211-213
Vichinsky et al. (1984) J. Pediatric 105:15-21
Cotes et al. (1983) Brit. J. Ostet. Gyneacol. 90:304-311
Haga et al. (1983) Acta Pediatr. Scand. 72:827-831
Claus-Walker (1983) Acta Pediatr. Scand. 72:827-831
Dunn et al. (1984) Eur. J. Appl. Physiol. 52:178-182
Miller et al. (1982) Brit. J. Haematol. 52:545-590
Upda et al. (1984) J. Lab. Clin. Med. 103:574-588
Dainiak et al. (1983) Cancer 5:1101-1106
Eschbach et al. (1987) N. Engl. J. Med. 316:73-78
Krantz and Goldwasser (1984) Proc. Natl. Acad. Sci. USA, 81:7574-7578
Branch et al. (1987) Blood 69:1782-1785
Mayeux et al. (1987) FEBS Letters 211:22-223
Mufson and Gesner (1987) Blood 69:1485-1490
Sakaguchi et al. (1987) Biochem. Biophys. Res. Commun. 146:7-12
Sawyer et al. (1987) Proc. Natl. Acad. Sci. USA, 84:3690-3694
Sawyer et al. (1987) J. Biol. Chem. 262:5554-5562
Todokoro et al. (1988) Proc. Natl. Acad. Sci. USA, 84:4126-4130
Amagnosou et al. (1990) Proc. Natl. Acad. Sci. USA, 87:5978-5982
Konishi et al. (1993) Brain Res. 609:29-35
Heldin, et al., Ligand-Induced Dimerization of Growth Factor Receptors: Variations on the Theme, Cytokine Growth Factor Rev., vol. 7 No. 1, pp. 3-10, 1996
Dorland's Illustrated Medical Dictionary, 27th Edition, pp. 1432-1433, 1988